Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Medtronic
Julphar
Moodys
Express Scripts
Deloitte
Cerilliant
Baxter
McKinsey

Generated: December 18, 2018

DrugPatentWatch Database Preview

ENTEREG Drug Profile

« Back to Dashboard

When do Entereg patents expire, and what generic alternatives are available?

Entereg is a drug marketed by Cubist Pharms and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has twenty patent family members in fourteen countries.

The generic ingredient in ENTEREG is alvimopan. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the alvimopan profile page.

Drug patent expirations by year for ENTEREG
Generic Entry Opportunity Date for ENTEREG
Generic Entry Date for ENTEREG*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for ENTEREG
Drug ClassOpioid Antagonist
Mechanism of ActionOpioid Antagonists
Synonyms for ENTEREG
[[(S)-2-Benzyl-3-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]propionyl]amino]acetic acid
053A893
145590-44-9
156053-89-3
170098-38-1 (dihydrate)
2-((S)-2-benzyl-3-((3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl)propanamido)acetic acid
2-[(2S)-2-benzyl-3-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]propanamido]acetic acid
2-[[(2S)-2-[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]methyl]-3-phenylpropanoyl]amino]acetic acid
2-[[(2S)-2-benzyl-3-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]propanoyl]amino]acetic acid
A11881
AC1NUQN6
ACN-047960
Adl 8-2698
AJ-45653
AK119795
AKOS015896476
Alvimopan
Alvimopan [INN]
Alvimopan anhydrous
Alvimopan, >=98% (HPLC)
anhydrous alvimopan
API0025949
AX8245211
BDBM50088381
C25H32N2O4
CHEBI:135686
CHEMBL270190
CS-0536
CTK8F0805
D0D7KC
DB06274
DTXSID60166035
Entereg (TN)
FT-0652843
Glycine, N-((2S)-2-(((3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl)methyl)-1-oxo-3-phenylpropyl)-
Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl
GTPL7471
HSDB 7704
HY-13243
I06-1921
LY 246736
LY-246736
LY246736
MFCD09838268
MolPort-006-167-841
Q153V49P3Z
RTX-013338
S036
SCHEMBL49578
SR-01000945029
SR-01000945029-1
ST24039017
ST24045942
trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine
UNII-Q153V49P3Z
W-5416
ZINC3802417

US Patents and Regulatory Information for ENTEREG

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cubist Pharms ENTEREG alvimopan CAPSULE;ORAL 021775-001 May 20, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Cubist Pharms ENTEREG alvimopan CAPSULE;ORAL 021775-001 May 20, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Cubist Pharms ENTEREG alvimopan CAPSULE;ORAL 021775-001 May 20, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Cubist Pharms ENTEREG alvimopan CAPSULE;ORAL 021775-001 May 20, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for ENTEREG
Drugname Dosage Strength RLD Date
➤ Subscribe Capsules 12 mg ➤ Subscribe ➤ Sign Up

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Medtronic
Julphar
Moodys
Express Scripts
Deloitte
Cerilliant
Baxter
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.